NFKB1 and cardiovascular disorder: Thus, by attenuating altered gut microbiome and increased microbial products (such as LPS) in patients with comorbidities like cardiovascular disease [74,75], 4 F reduces activation of the TLR and NF-κB pathways and associated lung injury in infections like SARS-CoV-2.